WOBURN, Mass. — October 19, 2025 — Leads & Copy — Replimune Group, Inc. (NASDAQ: REPL) presented data from a new analysis of the IGNYTE phase 2 cohort of RP1 plus nivolumab at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin. The analysis showed a 44% objective response rate in acral melanoma patients treated with RP1 and nivolumab, with a median duration of response of 11.9 months. The IGNYTE-3 phase 3 trial is currently recruiting patients with melanoma that has progressed on anti-PD1 and anti-CTLA-4 therapy.
Acral melanoma, a rare and aggressive skin cancer, often has poor outcomes and doesn’t respond well to therapies like immune checkpoint inhibitors. The IGNYTE phase 2 cohort included 140 patients with stage IIIB-IV cutaneous melanoma who had progressed on anti-PD1 therapy. RP1 was administered intratumorally with intravenous nivolumab.
RP1 (vusolimogene oderparepvec) is Replimune’s lead product candidate, engineered to maximize tumor killing potency and the activation of a systemic anti-tumor immune response. Replimune, headquartered in Woburn, MA, focuses on developing novel oncolytic immunotherapies.
Caroline Robert, M.D., Ph.D., presented the data at ESMO. Dirk Schadendorf, M.D., presented another poster on RP1 plus nivolumab in non-melanoma skin cancers.
Investor Inquiries: Chris Brinzey, ICR Healthcare, 339.970.2843, chris.brinzey@icrhealthcare.com
Media Inquiries: Arleen Goldenberg, Replimune, 917.548.1582, media@replimune.com
Source: Replimune Group, Inc.
